262 related articles for article (PubMed ID: 17275129)
1. R-Etodolac decreases beta-catenin levels along with survival and proliferation of hepatoma cells.
Behari J; Zeng G; Otruba W; Thompson MD; Muller P; Micsenyi A; Sekhon SS; Leoni L; Monga SP
J Hepatol; 2007 May; 46(5):849-57. PubMed ID: 17275129
[TBL] [Abstract][Full Text] [Related]
2. Targeting the beta-catenin/APC pathway: a novel mechanism to explain the cyclooxygenase-2-independent anticarcinogenic effects of celecoxib in human colon carcinoma cells.
Maier TJ; Janssen A; Schmidt R; Geisslinger G; Grösch S
FASEB J; 2005 Aug; 19(10):1353-5. PubMed ID: 15946992
[TBL] [Abstract][Full Text] [Related]
3. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21(CIP1) and inhibition of expression of cyclin D1.
Suzui M; Masuda M; Lim JT; Albanese C; Pestell RG; Weinstein IB
Cancer Res; 2002 Jul; 62(14):3997-4006. PubMed ID: 12124333
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological inhibition of beta-catenin in hepatoblastoma cells.
Ellerkamp V; Lieber J; Nagel C; Wenz J; Warmann SW; Fuchs J; Armeanu-Ebinger S
Pediatr Surg Int; 2013 Feb; 29(2):141-9. PubMed ID: 23266718
[TBL] [Abstract][Full Text] [Related]
5. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway.
Li T; Zhong J; Dong X; Xiu P; Wang F; Wei H; Wang X; Xu Z; Liu F; Sun X; Li J
Oncol Rep; 2016 Jun; 35(6):3614-22. PubMed ID: 27109804
[TBL] [Abstract][Full Text] [Related]
6. Effects of etodolac, a selective cyclooxygenase-2 inhibitor, on the expression of E-cadherin-catenin complexes in gastrointestinal cell lines.
Noda M; Tatsumi Y; Tomizawa M; Takama T; Mitsufuji S; Sugihara H; Kashima K; Hattori T
J Gastroenterol; 2002; 37(11):896-904. PubMed ID: 12483244
[TBL] [Abstract][Full Text] [Related]
7. Celecoxib inhibits β-catenin-dependent survival of the human osteosarcoma MG-63 cell line.
Xia JJ; Pei LB; Zhuang JP; Ji Y; Xu GP; Zhang ZP; Li N; Yan JL
J Int Med Res; 2010; 38(4):1294-304. PubMed ID: 20926002
[TBL] [Abstract][Full Text] [Related]
8. NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
Lu WJ; Chua MS; Wei W; So SK
Oncotarget; 2015 Oct; 6(30):29847-59. PubMed ID: 26359353
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of selective COX-2 inhibitors as therapeutic agents against canine mammary tumors.
Saito T; Tamura D; Asano R
Oncol Rep; 2014 Apr; 31(4):1637-44. PubMed ID: 24503782
[TBL] [Abstract][Full Text] [Related]
10. COX-2-dependent and COX-2-independent mode of action of celecoxib in human liver cancer cells.
Cervello M; Bachvarov D; Cusimano A; Sardina F; Azzolina A; Lampiasi N; Giannitrapani L; McCubrey JA; Montalto G
OMICS; 2011 Jun; 15(6):383-92. PubMed ID: 21410330
[TBL] [Abstract][Full Text] [Related]
11. Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2.
Lim K; Han C; Dai Y; Shen M; Wu T
Mol Cancer Ther; 2009 Nov; 8(11):3046-55. PubMed ID: 19887546
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib potentially inhibits metastasis of lung cancer promoted by surgery in mice, via suppression of the PGE2-modulated β-catenin pathway.
Zhang S; Da L; Yang X; Feng D; Yin R; Li M; Zhang Z; Jiang F; Xu L
Toxicol Lett; 2014 Mar; 225(2):201-7. PubMed ID: 24374173
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells.
Sakoguchi-Okada N; Takahashi-Yanaga F; Fukada K; Shiraishi F; Taba Y; Miwa Y; Morimoto S; Iida M; Sasaguri T
Biochem Pharmacol; 2007 May; 73(9):1318-29. PubMed ID: 17270149
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Cui W; Yu CH; Hu KQ
Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of tetrahydropyridinol derivatives on β-catenin signaling and invasion in human hepatocellular and breast carcinoma cells.
Yadunandam AK; Yoon JS; Jeong YT; Kim WY; Lee SY; Kim GD
Int J Mol Med; 2015 Aug; 36(2):577-87. PubMed ID: 26059838
[TBL] [Abstract][Full Text] [Related]
16. Potent cell growth inhibitory effects in hepatitis B virus X protein positive hepatocellular carcinoma cells by the selective cyclooxygenase-2 inhibitor celecoxib.
Xie H; Gao L; Chai N; Song J; Wang J; Song Z; Chen C; Pan Y; Zhao L; Sun S; Wu K; Feitelson MA; Liu J; Fan D
Mol Carcinog; 2009 Jan; 48(1):56-65. PubMed ID: 18506760
[TBL] [Abstract][Full Text] [Related]
17. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
18. Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/β-catenin/Tcf signaling pathway in human glioblastoma cells.
Sareddy GR; Kesanakurti D; Kirti PB; Babu PP
Neurochem Res; 2013 Nov; 38(11):2313-22. PubMed ID: 24013885
[TBL] [Abstract][Full Text] [Related]
19. Celecoxib suppresses hepatoma stemness and progression by up-regulating PTEN.
Chu TH; Chan HH; Kuo HM; Liu LF; Hu TH; Sun CK; Kung ML; Lin SW; Wang EM; Ma YL; Cheng KH; Lai KH; Wen ZH; Hsu PI; Tai MH
Oncotarget; 2014 Mar; 5(6):1475-90. PubMed ID: 24721996
[TBL] [Abstract][Full Text] [Related]
20. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis.
Leng J; Han C; Demetris AJ; Michalopoulos GK; Wu T
Hepatology; 2003 Sep; 38(3):756-68. PubMed ID: 12939602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
